IL149650A0 - Novel methods for the treatment and prevention of ileus - Google Patents

Novel methods for the treatment and prevention of ileus

Info

Publication number
IL149650A0
IL149650A0 IL14965000A IL14965000A IL149650A0 IL 149650 A0 IL149650 A0 IL 149650A0 IL 14965000 A IL14965000 A IL 14965000A IL 14965000 A IL14965000 A IL 14965000A IL 149650 A0 IL149650 A0 IL 149650A0
Authority
IL
Israel
Prior art keywords
ileus
methods
prevention
treatment
novel methods
Prior art date
Application number
IL14965000A
Other languages
English (en)
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of IL149650A0 publication Critical patent/IL149650A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14965000A 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus IL149650A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45092099A 1999-11-29 1999-11-29
PCT/US2000/042313 WO2001042207A2 (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus

Publications (1)

Publication Number Publication Date
IL149650A0 true IL149650A0 (en) 2002-11-10

Family

ID=23790061

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14965000A IL149650A0 (en) 1999-11-29 2000-11-29 Novel methods for the treatment and prevention of ileus
IL149650A IL149650A (en) 1999-11-29 2002-05-14 Piperidine n-alkylcarboxylate compounds for use as medicaments for the treatment and prevention of ileus

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149650A IL149650A (en) 1999-11-29 2002-05-14 Piperidine n-alkylcarboxylate compounds for use as medicaments for the treatment and prevention of ileus

Country Status (14)

Country Link
EP (1) EP1244448B1 (de)
JP (2) JP5079961B2 (de)
AT (1) ATE432076T1 (de)
AU (2) AU780738B2 (de)
CA (1) CA2393141C (de)
CY (1) CY1109264T1 (de)
DE (1) DE60042282D1 (de)
DK (1) DK1244448T3 (de)
ES (1) ES2329004T3 (de)
IL (2) IL149650A0 (de)
MX (1) MXPA02005336A (de)
NZ (1) NZ518684A (de)
PT (1) PT1244448E (de)
WO (1) WO2001042207A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
JP5176188B2 (ja) 2006-04-21 2013-04-03 ディーエスエム アイピー アセッツ ビー．ブイ． オピオイド受容体拮抗薬の使用
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP2565195B1 (de) 2007-03-29 2015-05-06 Wyeth LLC Peripherer Opioid-Rezeptor sowie Antagonisten und Verwendungen davon
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
RU2455943C1 (ru) * 2011-02-01 2012-07-20 Государственное образовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ лечения обтурационной формы острой спаечной тонкокишечной непроходимости

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1420015B1 (de) * 1959-10-16 1971-08-26 Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
FR2514644A1 (fr) * 1981-10-19 1983-04-22 Sanofi Sa Composition pharmaceutique a action antagoniste peripherique des opiaces
EP0103636B1 (de) * 1982-03-16 1990-09-12 Rockefeller University Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler störungen
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds

Also Published As

Publication number Publication date
DK1244448T3 (da) 2009-08-17
EP1244448A2 (de) 2002-10-02
CA2393141C (en) 2013-08-13
EP1244448A4 (de) 2003-06-25
IL149650A (en) 2011-02-28
CA2393141A1 (en) 2001-06-14
AU2005203041B2 (en) 2009-01-08
ATE432076T1 (de) 2009-06-15
JP2012162560A (ja) 2012-08-30
JP2003517476A (ja) 2003-05-27
EP1244448B1 (de) 2009-05-27
PT1244448E (pt) 2009-06-30
JP5079961B2 (ja) 2012-11-21
DE60042282D1 (de) 2009-07-09
NZ518684A (en) 2003-11-28
WO2001042207A3 (en) 2002-05-02
AU3970501A (en) 2001-06-18
ES2329004T3 (es) 2009-11-20
JP5460771B2 (ja) 2014-04-02
WO2001042207A2 (en) 2001-06-14
AU2005203041A1 (en) 2005-08-04
AU780738B2 (en) 2005-04-14
CY1109264T1 (el) 2014-07-02
MXPA02005336A (es) 2003-01-28

Similar Documents

Publication Publication Date Title
CY1109264T1 (el) Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου
WO2001041705A3 (en) Novel methods for the treatment and prevention of dizziness and pruritus
HK1055078A1 (zh) 使用纳布啡和鸦片拮抗剂治疗疼痛的方法
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
IL149378A0 (en) Composition for treatment of constipation and irritable bowel syndrome
NZ331001A (en) Use of an opiate K receptor agonist as an antipruritic
WO2003070191A8 (en) Tamper-resistant transdermal opioid delivery devices
IL134796A0 (en) Noribogaine in the treatment of pain and drug addiction
WO2004096122A3 (en) Use of ngf antagonists and opioids for treating pain
DE69841663D1 (de) Verwendung von methylnaltrexon und verwandten verbindungen
CA2312234A1 (en) Use of methylnaltrexone and related compounds
AU5914201A (en) Intrathecal administration of rituximab for treatment of central nervous system lymphomas
RU2000119779A (ru) Способ предотвращения злоупотребления содержащими опиоиды лекарственными формами
CA2548834A1 (en) Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
EP0915094A4 (de) Morphinanderivate und ihre medizinische Anwendung
MXPA03007885A (es) Norbuprenorfina n-but-3-enilo y metodos de uso.
DE502007003589D1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
CA2430281A1 (en) Use of weak opioids and mixed opioid agonists/antagonists for treatment of urinary incontinence
MY133596A (en) Compound and method for the treatment of pain
HK1080004A (en) Methods for treating pain by administering a nerve growth factor antagonist and an opioid analgesic and compositions containing the same
EP1095655A3 (de) NK-1 Rezeptor Antagonisten und Eletriptan zur Behandlung von Migräne
IT1260498B (it) Composizioni terapeutiche a rilascio ritardato atte ad inibire l'assunzione di oppiacei

Legal Events

Date Code Title Description
FF Patent granted